Nanobiotix share declines 1% but posts +22% on the week
The Parisian oncological nanomedicine biotech slips slightly in mid-morning trading, in a Paris market clearly oriented downward. This modest pullback comes after a marked weekly rebound, which brought the stock back toward its short-term technical benchmarks.
A limited decline that contrasts with a SBF 120 in sharp retreat
Nanobiotix loses 0.83% to €23.86, while the SBF 120 drops 1.47% and the CAC 40 falls 1.51%. The stock thus ranks in the middle of the broader index, significantly less affected than the market. Over the week, it still shows a gain of nearly 22%, but it remains down 19.55% over one month and 28.56% over three months.
Sector comparables do not send a homogeneous signal: Sanofi declines 0.87%, with -1.96% over one month, while Eurofins Scientific advances 1.41% and gains 3.9% over the same period. The Paris market is moreover evolving in a context of elevated French rates, with the 10-year OAT at 4.99% according to the Banque de France survey of October 21.
A 20-day moving average reclaimed, a 50-day moving average still 18% above the price
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The week's rebound brought the price to 4.19% above its 20-day MA (€22.90), a level that the stock had lost during the month's slide. The 50-day MA, at €29.06, meanwhile remains nearly 18% above the price, and the 200-day MA at €28.86 in the same range: the underlying trend remains downward. The RSI at 48 is neutral, after falling to 22.8 on October 19.
The company had published on September 24 its financial update for the first half of 2026, with €110.9 million in cash, an amount that would allow it to finance its operations through 2029. On levels, support at €18.85 and resistance at €31.30 bound the current trading zone.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
